Improved tumor infiltration of CD8+ T‐cells has been linked to improved prognostic outcomes, suggesting these results are therapeutically relevant.[52] Our findings are consistent with previous studies indicating that IRF5 therapy increases CD8+ T‐cell tumor infiltration.[20, 51] We also observed that the B‐cell proportion of TILs was lower in the MCTN‐IRF5‐treated group, comprising an average of 1.25% of TILs, compared with 11.9% for the vehicle group (Figure 6C). Here, IRF5 is linked to neoplasm.